menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

5 0
yesterday

Get Quartz in your inbox

Free daily briefing on global business news.

Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324

Jeff Schear / Getty Images

Johnson & Johnson $JNJ agreed to acquire Ollin Biosciences, a clinical-stage drugmaker focused on treatments for serious eye diseases, in a deal worth $2.2 billion upfront, the company said on Monday.

The agreement also provides for as much as $1.125 billion in additional payments if certain........

© Quartz